Gritstone bio, Inc. (GRTS)

0,7645 -0,0484 (-5,95%) Al cierre: 04:00PM EDT

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 231

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.	Co-Founder, President, CEO & Director	983,44k	N/A	1966
Mr. Erin E. Jones M.S.	Executive VP & COO	658,01k	N/A	1972
Dr. Karin Jooss Ph.D.	Executive VP and Head of Research & Development	706,07k	N/A	1966
Ms. Vassiliki Economides	Executive VP & CFO	N/A	N/A	1981
Mr. James Cho	Chief Accounting Officer	N/A	N/A	N/A
George MacDougall	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Stacy Proctor	Executive VP & Chief People Officer	N/A	N/A	N/A
Dr. Matthew J. Hawryluk M.B.A., Ph.D.	Executive VP & Chief Business Officer	N/A	N/A	1979

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gobierno corporativo

El ISS Governance QualityScore de Gritstone bio, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 2; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.